Roche has revealed the data behind a positive phase 3 trial for its oral BTK inhibitor fenebrutinib in primary progressive multiple sclerosis (PPMS), revealing that it was at least as effective as its ...

Too many digital twin initiatives stall after the pilot phase, failing to deliver real business impact. Without a trusted data foundation, companies risk costly downtime, inaccurate predictions, and ...